InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,599.60
(
1.04%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.34
(
-0.17%
)
Bitcoin
63,789.20
(
0.99%
)
Post# of 27676
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

onthegreen

Send PM Follow Ignore
Followers 51
Posts 7979
Boards Moderated 0
Alias Born 05/13/2014

onthegreen

Re: None

Thursday, 10/08/2015 9:54:43 AM

Thursday, October 08, 2015 9:54:43 AM

Post# of 27676
BEVERLY HILLS, Calif., Oct. 7, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company") announced today it has entered into an agreement with Theradex Systems, Inc. ("Theradex"), a leading global contract research organization ("CRO") with extensive expertise in oncology clinical development. Through this new partnership, Theradex will lead the Company in finalizing the Investigational New Drug Application (IND #124642) with the U.S. FDA for Rich's lead drug RP-323 in patients with AML.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up